

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.811

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 159** Bout of the corner men and not the boxers? Contextual effects flex their muscles
M Englund

Viewpoint

- 162** The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
L Calabrese, X Mariette

Recommendation

- 165** Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
J Kay, M M Schoels, T Dörner, P Emery, T K Kvien, J S Smolen, F C Breedveld, on behalf of the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases

Review

- 175** Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
K F Baker, J D Isaacs

Clinical and epidemiological research

- 188** Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial
R Sihvonen, M Paavola, A Malmivaara, A Itälä, A Joukainen, H Nurmi, J Kalske, A Ikonen, T Järvelä, T A H Järvinen, K Kanto, J Karhunen, J Knif Sund, H Kröger, T Kääriäinen, J Lehtinen, J Nyrhinen, J Paloneva, O Päiväniemi, M Raivio, J Sahlman, R Sarvlinna, S Tukiainen, V-V Välimäki, V Äärilä, P Toivonen, T L N Järvinen, The FIDELITY (Finnish Degenerative Meniscal Lesion Study) Investigators
- 196** Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts
M Barbhuiya, S K Tedeschi, B Lu, S Malspeis, D Kreps, J A Sparks, E W Karlson, K H Costenbader

- 203** Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants
J Rönnelid, M Hansson, L Mathsson-Alm, M Cornillet, E Reed, P-J Jakobsson, L Alfredsson, R Holmdahl, K Skriver, G Serre, K Lundberg, L Klareskog

- 212** Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
D Khanna, C P Denton, C J F Lin, J M van Laar, T M Frech, M E Anderson, M Baron, L Chung, G Fierlbeck, S Lakshminarayanan, Y Allamore, J E Pope, G Riemekasten, V Steen, U Müller-Ladner, H Spotswood, L Burke, J Siegel, A Jahreis, D E Furst

- 221** Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARC trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis
M Dougados, W P Maksymowych, R B M Landewé, A Moltó, P Claudepierre, M de Hooge, R G Lambert, R Bonin, J F Bukowski, H E Jones, I Logeart, R Pedersen, A Szumski, B Vlahos, D van der Heijde

- 228** Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
X Mariette, F Förger, B Abraham, A D Flynn, A Moltó, R-M Flipo, A van Tubergen, L Shaughnessy, J Simpson, M Teil, E Helmer, M Wang, E F Chakeravarty

- 234** Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
J S Smolen, J-Y Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, A Baranaukskaite, R Yatsyshyn, M Meleic, W Porawska, H Ciferska, K Jedrychowicz-Rosiak, A Zielinska, Y Lee, Y H Rho

MORE CONTENTS ►



EDITOR'S CHOICE



OPEN ACCESS

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008

JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 241** Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research



L J McCann, C A Pilkington, A M Huber, A Ravelli, D Appelbe, J J Kirkham, P R Williamson, A Aggarwal, L Christopher-Stine, T Constantin, B M Feldman, I Lundberg, S Maillard, P Mathiesen, R Murphy, L M Pachman, A M Reed, L G Rider, A van Royen-Kerkof, R Russo, S Spinty, L R Wedderburn, M W Beresford

- 251** Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort

L J J van Mens, M G H van de Sande, A W R van Kuijk, D Baeten, L C Coates

- 258** Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire



L Gossec, P Chauvin, A Saraux, C Hudry, G Cukierman, T de Chalus, C Dreuillet, V Saulot, S Tong, F Russo-Marie, J-M Joubert, F Berenbaum

- 264** Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study

C Götestam Skorpen, S Lydersen, I-M Gilboe, J F Skomsvoll, K Å Salvesen, Øyvind Palm, H S Svean Koksvik, B Jakobsen, M Wallenius

- 270** Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study



H Yamanaka, S Tamaki, Y Ide, H Kim, K Inoue, M Sugimoto, Y Hidaka, A Taniguchi, S Fujimori, T Yamamoto

- 277** Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study

R Charlton, A Green, G Shaddick, J Snowball, A Nightingale, W Tillet, C H Smith, N McHugh, on behalf of the PROMPT study group

- 281** Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers

R L Coratz, K Zobbe, P Højgaard, L E Kristensen, S Overgaard, A Odgaard, H Lindegaard, L Dreyer

- 289** Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis



A Kavanaugh, R F van Vollenhoven, R Fleischmann, P Emery, I Sainsbury, S Florentinus, S Chen, B Guérette, H Kupper, J S Smolen

- 293** Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort

A de Koning, F de Bruin, R van den Berg, S Ramiro, X Baraliakos, J Braun, F A van Gaalen, M Reijnen, D van der Heijde

Basic and translational research

- 300** Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint



B Smiljanovic, A Radzikowska, E Kuca-Warnawin, W Kurovska, J R Grün, B Stuhlmueller, M Bonin, U Schulte-Wrede, T Sørensen, C Kyogoku, A Bruns, S Hermann, S Ohrndorf, K Aupperle, M Backhaus, G R Burmester, A Radbruch, A Grützkau, W Maslinski, T Häupl

Letters

- 310** Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study

R Wittoek, P Carron, B Lambert, P Meersseman, G Verbruggen, F Van den Bosch, D Elewaut

- 311** The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases

H J Siddle, P Mandl, D Aletaha, T P V Vlieland, M Backhaus, P Cornell, M-A D'Agostino, K Ellegaard, A Iagnocco, B Jakobsen, T Jasinski, N H Kildal, M Lehner, I Möller, G M Supp, P O'Connor, A C Redmond, E Naredo, R J Wakefield

- 313** Plasma oxypurinol as a measure of adherence in clinical trials

L K Siamp, T Merriman, C Frampton, M Zhang, M Wallace, J N Miner, N Dalbeth

- 315** Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis

C Deng, A Bianchi, N Presle, D Moulin, M Koufany, C Guillaume, H Kempf, A Pizard

Electronic pages**Correspondence**

- e6** Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis
M Samson, T Ghesquière, S Berthier, B Bonnotte
- e7** Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson *et al*
R Conway, U Fearon, E S Molloy
- e8** ANCA-associated vasculitis: mission incomplete
S V Moiseev, P I Novikov, I Smitienko
- e9** Response to: 'Mortality in ANCA-associated vasculitis: mission incomplete' by Moiseev *et al*
J A Avina-Zubieta, N Delghan, J A Tan
- e10** Comment on CONCEPT by Reginster *et al*: are the authors' interpretations supported by the data analysis?
S Kardeş
- e11** CONCEPT provides robust evidence that chondroitin sulfate is superior to placebo and similar to celecoxib in the symptomatic management of osteoarthritis
J-Y L Reginster, on behalf of CONCEPT Investigation Group